CO6400150A2 - Proteína de enlace de il-13 - Google Patents

Proteína de enlace de il-13

Info

Publication number
CO6400150A2
CO6400150A2 CO11162427A CO11162427A CO6400150A2 CO 6400150 A2 CO6400150 A2 CO 6400150A2 CO 11162427 A CO11162427 A CO 11162427A CO 11162427 A CO11162427 A CO 11162427A CO 6400150 A2 CO6400150 A2 CO 6400150A2
Authority
CO
Colombia
Prior art keywords
link protein
antigen binding
binding proteins
mabdabs
ipf
Prior art date
Application number
CO11162427A
Other languages
English (en)
Spanish (es)
Inventor
Claire Ashman
Jonathan Henry Ellis
Martin Anibal Orecchia
Alan Peter Lewis
Paul Andrew Hamblin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO6400150A2 publication Critical patent/CO6400150A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CO11162427A 2009-05-28 2011-11-25 Proteína de enlace de il-13 CO6400150A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18183309P 2009-05-28 2009-05-28
US28893009P 2009-12-22 2009-12-22

Publications (1)

Publication Number Publication Date
CO6400150A2 true CO6400150A2 (es) 2012-03-15

Family

ID=42335086

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11162427A CO6400150A2 (es) 2009-05-28 2011-11-25 Proteína de enlace de il-13

Country Status (21)

Country Link
US (2) US20100303821A1 (OSRAM)
EP (1) EP2435481A1 (OSRAM)
JP (1) JP5919188B2 (OSRAM)
KR (1) KR20120034679A (OSRAM)
CN (1) CN102459341A (OSRAM)
AR (1) AR078047A1 (OSRAM)
AU (1) AU2010251955A1 (OSRAM)
BR (1) BRPI1016061A2 (OSRAM)
CA (1) CA2763443A1 (OSRAM)
CO (1) CO6400150A2 (OSRAM)
CR (1) CR20110664A (OSRAM)
DO (1) DOP2011000347A (OSRAM)
EA (1) EA201190275A1 (OSRAM)
IL (1) IL216261A0 (OSRAM)
MA (1) MA33381B1 (OSRAM)
MX (1) MX2011012622A (OSRAM)
PE (1) PE20120401A1 (OSRAM)
SG (1) SG176203A1 (OSRAM)
TW (1) TW201107345A (OSRAM)
UY (1) UY32664A (OSRAM)
WO (1) WO2010136481A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
ATE509033T1 (de) 2006-03-20 2011-05-15 Univ California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
JP6126773B2 (ja) 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
JP5919188B2 (ja) 2009-05-28 2016-05-18 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｉｌ−１３結合タンパク質
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
CA2896764C (en) * 2013-01-03 2023-10-31 Meso Scale Technologies, Llc Assay panels
CN105307676A (zh) * 2013-04-05 2016-02-03 豪夫迈·罗氏有限公司 抗il-4抗体和双特异性抗体及其用途
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
US9840553B2 (en) * 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
CN115960230A (zh) 2015-08-07 2023-04-14 伊麦吉纳博公司 靶向分子的抗原结合构建体
MA43025A (fr) * 2015-10-02 2021-05-26 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3
KR20240052871A (ko) 2016-04-27 2024-04-23 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
CN118005784A (zh) * 2022-11-08 2024-05-10 上海洛启生物医药技术有限公司 抗il-13长效纳米抗体序列及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
WO2003092610A2 (en) 2002-05-01 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat hiv infection and aids
GB0414799D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Immunoglobulins
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
AU2007209202A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind IL-4 and/or IL-13
EP1976991A1 (en) 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
DE112008003232T5 (de) 2007-11-30 2011-02-24 Glaxo Group Limited, Greenford Antigen-Bindungskonstrukte
SG2014014138A (en) 2008-03-31 2014-07-30 Genentech Inc Compositions and methods for treating and diagnosing asthma
JP5919188B2 (ja) 2009-05-28 2016-05-18 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｉｌ−１３結合タンパク質

Also Published As

Publication number Publication date
JP2012528110A (ja) 2012-11-12
JP5919188B2 (ja) 2016-05-18
KR20120034679A (ko) 2012-04-12
TW201107345A (en) 2011-03-01
SG176203A1 (en) 2011-12-29
BRPI1016061A2 (pt) 2016-09-13
AR078047A1 (es) 2011-10-12
EP2435481A1 (en) 2012-04-04
EA201190275A1 (ru) 2012-11-30
IL216261A0 (en) 2012-01-31
WO2010136481A1 (en) 2010-12-02
MA33381B1 (fr) 2012-06-01
MX2011012622A (es) 2011-12-14
UY32664A (es) 2010-12-31
US8680245B2 (en) 2014-03-25
US20120082682A1 (en) 2012-04-05
PE20120401A1 (es) 2012-05-04
US20100303821A1 (en) 2010-12-02
AU2010251955A1 (en) 2011-12-22
DOP2011000347A (es) 2012-01-15
CR20110664A (es) 2012-02-27
CA2763443A1 (en) 2010-12-02
CN102459341A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
CO6400150A2 (es) Proteína de enlace de il-13
NI201100040A (es) Anticuerpos anti-il-13 modificados, composiciones, métodos y usos.
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
MX358249B (es) Proteínas de enlace al antígeno il-23 humanas.
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
BR112012021329A2 (pt) anticorpo monoclonal anti-tnf-<244> completamente humano, método de preparação e uso do mesmo.
AR076655A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
MX2021001494A (es) Anticuerpos dkk1 y metodos de uso.
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
MX361337B (es) Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares.
DOP2011000189A (es) Proteinas de enlace de miostatina
CR20120404A (es) Proteinas de enlace cd127
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
CO6640254A2 (es) Método para preparar anticuerpos con propiedades mejoradas
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
CL2014000927A1 (es) Proteinas naglu humana recombinante y usos de la misma
EA201591133A1 (ru) СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19
ECSP13012536A (es) Composiciones de anticuerpo y métodos de uso
EA201391440A1 (ru) Производные пиразолопиримидина
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
UY31378A1 (es) Inmunoglobulinas
UY33043A (es) Proteinas de enlace de antigenos anti-orai 1 y usos de las mismas

Legal Events

Date Code Title Description
FA Application withdrawn